This article unpacks the latest scientific findings and their implications for the future of cancer treatment.
Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC). Rucaparib vs docetaxel (DTX) or second-generation androgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback